Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eyecyte-RPE
- Development stage
- Phase 2
- Lead developer
- Eyestem Research
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Subretinal
01
Overview
Eyecyte-RPE is an allogeneic cell therapy consisting of a suspension of retinal pigment epithelium (RPE) cells derived from human induced pluripotent stem cells (hiPSCs). Developed by Eyestem Research, it is designed to treat geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The therapy aims to replace damaged or lost RPE cells in the macula, which are essential for the metabolic support and survival of photoreceptors. By restoring the RPE layer, Eyecyte-RPE potentially enables tissue regeneration and arrests the progression of vision loss. The product is formulated as a cryopreserved, scalable suspension administered via a single subretinal injection. Clinical data from Phase 1 trials have demonstrated a favorable safety profile and significant improvements in visual acuity, with some patients showing early signs of disease reversal.
- Brand names
- Eyecyte-RPE
- Other names
- hiPSC-derived RPE cellsEyecyte-RPE suspension
Beyond the preview
Go deeper on Eyecyte-RPE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eyecyte-RPE.